Looking for a Nice Rebound to 31

NASDAQ:MYGN   Myriad Genetics, Inc
I think this stock will recover some of it's losses, regardless of the outcome of the potential FDA restrictions on drug suggestions. The stock has a solid business model and the company has said they are seeing increased demand. This new fields of genetics testing still needs to establish itself in the healthcare payer ecosystem, which presents some risk, but all in all I think the fundamentals are sound, making this a buying opportunity.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.